358 related articles for article (PubMed ID: 9399940)
1. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
Sovak MA; Bellas RE; Kim DW; Zanieski GJ; Rogers AE; Traish AM; Sonenshein GE
J Clin Invest; 1997 Dec; 100(12):2952-60. PubMed ID: 9399940
[TBL] [Abstract][Full Text] [Related]
2. The ability of CD40L, but not lipopolysaccharide, to initiate immunoglobulin switching to immunoglobulin G1 is explained by differential induction of NF-kappaB/Rel proteins.
Lin SC; Wortis HH; Stavnezer J
Mol Cell Biol; 1998 Sep; 18(9):5523-32. PubMed ID: 9710636
[TBL] [Abstract][Full Text] [Related]
3. Nerve growth factor-dependent activation of NF-kappaB contributes to survival of sympathetic neurons.
Maggirwar SB; Sarmiere PD; Dewhurst S; Freeman RS
J Neurosci; 1998 Dec; 18(24):10356-65. PubMed ID: 9852573
[TBL] [Abstract][Full Text] [Related]
4. Acute exercise activates myocardial nuclear factor kappa B.
Balan M; Locke M
Cell Stress Chaperones; 2011 Jan; 16(1):105-11. PubMed ID: 20694538
[TBL] [Abstract][Full Text] [Related]
5. Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells.
Miyamoto S; Seufzer BJ; Shumway SD
Mol Cell Biol; 1998 Jan; 18(1):19-29. PubMed ID: 9418849
[TBL] [Abstract][Full Text] [Related]
6. Integrated molecular modeling and dynamics approaches revealed potential natural inhibitors of NF-κB transcription factor as breast cancer therapeutics.
Zubair M; Khalil S; Rasul I; Nadeem H; Noor F; Ahmad S; Alrumaihi F; Allemailem KS; Almatroudi A; Alshehri FF; Alshehri ZS
J Biomol Struct Dyn; 2023; 41(24):14715-14729. PubMed ID: 37301608
[TBL] [Abstract][Full Text] [Related]
7. Co-imaging of RelA and c-Rel reveals features of NF-κB signaling for ligand discrimination.
Rahman SMT; Singh A; Lowe S; Aqdas M; Jiang K; Vaidehi Narayanan H; Hoffmann A; Sung MH
Cell Rep; 2024 Mar; 43(3):113940. PubMed ID: 38483906
[TBL] [Abstract][Full Text] [Related]
8. NF-κB subunits direct kinetically distinct transcriptional cascades in antigen receptor-activated B cells.
Zhao M; Chauhan P; Sherman CA; Singh A; Kaileh M; Mazan-Mamczarz K; Ji H; Joy J; Nandi S; De S; Zhang Y; Fan J; Becker KG; Loke P; Zhou W; Sen R
Nat Immunol; 2023 Sep; 24(9):1552-1564. PubMed ID: 37524800
[TBL] [Abstract][Full Text] [Related]
9. NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer.
Lalle G; Lautraite R; Bouherrou K; Plaschka M; Pignata A; Voisin A; Twardowski J; Perrin-Niquet M; Stéphan P; Durget S; Tonon L; Ardin M; Degletagne C; Viari A; Belgarbi Dutron L; Davoust N; Postler TS; Zhao J; Caux C; Caramel J; Dalle S; Cassier PA; Klein U; Schmidt-Supprian M; Liblau R; Ghosh S; Grinberg-Bleyer Y
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38563819
[TBL] [Abstract][Full Text] [Related]
10. NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB.
Kabacaoglu D; Ruess DA; Ai J; Algül H
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31277415
[TBL] [Abstract][Full Text] [Related]
11. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression.
Zhang M; Liu ZZ; Aoshima K; Cai WL; Sun H; Xu T; Zhang Y; An Y; Chen JF; Chan LH; Aoshima A; Lang SM; Tang Z; Che X; Li Y; Rutter SJ; Bossuyt V; Chen X; Morrow JS; Pusztai L; Rimm DL; Yin M; Yan Q
Sci Transl Med; 2022 Feb; 14(630):eabf5473. PubMed ID: 35108062
[TBL] [Abstract][Full Text] [Related]
12. Subunit-Specific Role of NF-κB in Cancer.
Kaltschmidt B; Greiner JFW; Kadhim HM; Kaltschmidt C
Biomedicines; 2018 Apr; 6(2):. PubMed ID: 29673141
[TBL] [Abstract][Full Text] [Related]
13. miRNA-214-3p stimulates carcinogen-induced mammary epithelial cell apoptosis in mammary cancer-resistant species.
Harman RM; Das SP; Kanke M; Sethupathy P; Van de Walle GR
Commun Biol; 2023 Oct; 6(1):1006. PubMed ID: 37789172
[TBL] [Abstract][Full Text] [Related]
14. Global Interactome Mapping Reveals Pro-tumorigenic Interactions of NF-κB in Breast Cancer.
Lapcik P; Stacey RG; Potesil D; Kulhanek P; Foster LJ; Bouchal P
Mol Cell Proteomics; 2024 Apr; 23(4):100744. PubMed ID: 38417630
[TBL] [Abstract][Full Text] [Related]
15. Optical controlled and nuclear targeted CECR2 competitor to downregulate CSF-1 for metastatic breast cancer immunotherapy.
Cen Y; Chen Y; Li X; Chen X; Yu B; Yan M; Yan N; Cheng H; Li S
Biomaterials; 2024 Jul; 308():122568. PubMed ID: 38615488
[TBL] [Abstract][Full Text] [Related]
16. Rel-A/PACER/miR 7 Axis May Play a Role in Radiotherapy Treatment in Breast Cancer Patients.
Fazlollah S; Hossein M; Mir Davood O
Iran Biomed J; 2023 Jul; 27(4):173-82. PubMed ID: 37507347
[TBL] [Abstract][Full Text] [Related]
17. A novel role of MNT as a negative regulator of REL and the NF-κB pathway.
Liaño-Pons J; Lafita-Navarro MC; García-Gaipo L; Colomer C; Rodríguez J; von Kriegsheim A; Hurlin PJ; Ourique F; Delgado MD; Bigas A; Espinosa L; León J
Oncogenesis; 2021 Jan; 10(1):5. PubMed ID: 33419981
[TBL] [Abstract][Full Text] [Related]
18. Dietary phytochemicals as potent chemotherapeutic agents against breast cancer: Inhibition of NF-κB pathway via molecular interactions in rel homology domain of its precursor protein p105.
Khan MK; Ansari IA; Khan MS
Pharmacogn Mag; 2013 Jan; 9(33):51-7. PubMed ID: 23661994
[TBL] [Abstract][Full Text] [Related]
19. A structured environment helps to regulate nuclear architecture in breast epithelial cells.
Bridger JM; Kill IR
Cell Cycle; 2016 May; 15(9):1178-9. PubMed ID: 27078818
[No Abstract] [Full Text] [Related]
20. MyD88 signaling pathways: role in breast cancer.
Zheng H; Wu X; Guo L; Liu J
Front Oncol; 2024; 14():1336696. PubMed ID: 38347830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
